Bloomberg News: J&J nearing deal to pay $1 billion over Risperdal marketing

by Ben Vernia | January 8th, 2012

On January 6, Bloomberg news reported that the Johnson & Johnson is nearing an agreement with the U.S. Attorney’s Office for the Eastern District of Pennsylvania to pay more than $1 billion to resolve civil claims that it marketed the atypical (or second generation) antipsychotic drug Risperdal. A company spokesperson refused to comment on what she described as “rumor or speculation.”

In May 2011, J&J announced that it was setting aside a reserve in an undisclosed amount for a potential resolution. In January 2010, DOJ intervened in a suit in Massachusetts, alleging that the company paid kickbacks to long-term care pharmacy Omnicare to buy and recommend Risperdal.

No Responses to “Bloomberg News: J&J nearing deal to pay $1 billion over Risperdal marketing”

  1. All the atypical antipsychotic drug makers cashed in on the $15 per pill profit maker.
    Same with Seroquel,it turns out they are NO safer than Thorazine. My doctor swears that Zyprexa,Risperdal,Seroquel STILL cause Tardive Dyskinesia almost as much as the old cheaper meds.
    The atypicals cause diabetes in the group of state medicaid dependent mental patients and now the state of Texas has to pay for the diabetes.The old cheaper meds did not cause deadly diabetes.
    Get the picture now why this scandal is so egregious?
    — Daniel Haszard Zyprexa victim activist.

    FMI zyprexa-victims(dot)com

Leave a Reply

Recent Posts

Recent Comments